Supplementary Results

Androgen biosynthesis in neonates with CAH due to P450 oxidoreductase deficiency
We were able to longitudinally collect spot urines in three neonates affected by PORD. All three neonates had a 46,XY karyotype. We previously reported genotype and phenotype of the three PORD neonates as part of a larger PORD cohort (1); in that paper, patients 1, 2 and 3 were reported as patients 8, 16 , and 17, respectively); below we have briefly summarized information on genotype and the key clinical characteristics they presented with at birth.
Patient 1 (46,XY; POR A287P/A287P) was born at 34 weeks of gestation of a twin pregnancy; his clinically unaffected twin sister (46,XX) is heterozygous for POR A287P. At birth, his external genitalia had normal male appearance, with bilaterally descended testes. Patient 2 (46,XY; POR A287P/A287P) was born at 35 weeks gestation and is the younger sibling of a girl who had been born with severe virilization (46,XX DSD). Patient 2 presented with normal male genitalia including bilaterally descended testes.
Patient 3 (46,XY; POR A287P/G188_V191dup) was born at full term. During the second and third trimester the mother had reported the development of facial acne and slight coarsening of facial features, which both quickly resolved after birth. At birth, there were overt signs of undervirilization (46,XY DSD) with a small midline phallus measuring 1.5cm, a bifid scrotum with palpable testes and perineoscrotal hypospadias.
As patient 3 is compound heterozygous for the major loss-of-function mutant G188_V191dup, his combined residual POR activity can be assumed to be lower than in patients 1 and 2, who are compound heterozygous for POR A287P, a missense mutation previously shown to have considerable residual activity.
This difference in residual POR activity is also supported by their malformation phenotypes, which occurs in PORD most likely due to impaired function of CYP enzymes involved in sterol biosynthesis and retinoic acid metabolism. While the two boys homozygous for POR A287P presented with only mild to moderate malformations, patient 3 had a more severe malformation phenotype (1).
Interestingly, maternal virilization was only observed during the pregnancy with patient 3 and not in the two boys with homozygous POR A287P; maternal virilization was only observed in one of five previously reported pregnancies affected by homozygous POR A287P mutations (2) . As POR A287P has previously been shown not to impair CYP19A1 aromatase activity (3), it is tempting to assume that impaired placental aromatase activity is an important contributor to maternal virilization, as also previously proposed by others (4, 5) .
Differential effects of POR mutants on sex steroid biosynthesis
Both the classic and the alternative pathway to androgens require the 17,20-lyase activity of the steroidogenic enzyme CYP17A1. In the classic pathway, CYP17A1 converts 17-hydroxypregnenolone to DHEA and can also convert 17-hydroxyprogesterone (17OHP) to androstenedione ( Fig. S1A) . However, in humans, the latter reaction occurs with significantly lower efficacy (6) and, thus, only provides a relevant contribution to androgen synthesis if 17OHP accumulates, a pathognomonic finding in congenital adrenal hyperplasia with impaired 21-hydroxylase activity, typically due to inactivating CYP21A2 mutations.
The proposed alternative androgen synthesis pathway starts with 17OHP and requires CYP17A1 17,20 lyase activity further downstream, to convert 5α-17-hydroxyallopregnanolone (5α-17HP) to androsterone. That reaction is strongly preferred by the human CYP17A1 enzyme (7) , which means if 17,20 lyase activity is partially compromised, alternative pathway activity is the most likely one to still occur.
In congenital adrenal hyperplasia due to POR deficiency, the relationship between genotype and genital phenotype has a broad spectrum and its assessment is complicated by the fact that the majority of affected individuals are compound heterozygous (1, 4, 8) . In our previously published cohort of 30 patients
(1) we identified six individuals homozygous for POR A287P, four with 46,XX DSD whereas the two 46,XY individuals had normal male external genitalia. We recently identified two sisters homozygous for POR H628P, previously only described in the compound heterozygous state. The older sister had presented with primary amenorrhea and unambiguously female external genital appearance; chromosome analysis confirmed 46,XY DSD. Her younger sister had a 46,XX karyotype and normal female genitalia. Thus, the genital phenotypes relating to these two homozygous POR mutations represent exact mirror images, with 46,XX DSD for A287P and 46,XY DSD for H628P, respectively; however, in all affected individuals postnatal circulating androgens were found to be low. We hypothesized that this difference might be explained by a differential impact of the two mutations on CYP17A1 17,20 lyase activity within the classic and alternative androgen pathways during human fetal development.
To test this, we employed yeast microsomes co-expressing human CYP17A1 with human wild-type and mutant POR, respectively, and incubated them with the substrates for the classic and alternative androgen biosynthesis pathways, respectively, 17-hydroxypregnenolone (17-Preg) and 5α-17hydroxypregnanolone (5α-17HP). Comparison of the two POR mutants revealed that A287P retained significantly higher activity than H628P in both the classic and the alternative androgen pathway conversions ( Fig. S1A+B) . POR A287P demonstrated higher activity in the alternative than in the classic androgen pathway, providing quantitative evidence supporting a more significant contribution of the alternative androgen pathway in conveying prenatal virilization in 46,XX individuals homozygous for POR A287P. CYP17A1 co-expressed with wild-type POR also exhibited slightly higher activity in the alternative vs. the classic androgen pathway conversion ( Fig. S1A+B) , consistent with the previous report describing 5α-17HP as the preferred CYP17A1 substrate (7) .
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The enzyme P450 aromatase (CYP19A1) also requires POR as an electron donor and patients with inactivating CYP19A1 mutations develop androgen excess due to decreased conversion of androgens to estrogens (9) . Thus, it is theoretically possible that reduced androgen synthesis via the classic pathway could still result in androgen excess, dependent on the distinct effect of a specific POR mutant on CYP19A1 activity, as suggested previously (3, 4, 10) . To exclude a role of impaired aromatization in the observed genital phenotype differences, we also examined the influence of POR mutants A287P and H628P on CYP19A1 activity, again employing a humanized yeast microsomal co-expression assay. Both POR mutants showed similar aromatase activity to wild-type POR for the conversion of androstenedione to estrone, when co-expressed with CYP19A1. These findings exclude impaired aromatization as the cause of the observed genital phenotype differences (Fig. S1C) , also corroborating a previous report demonstrating normal aromatase activity in the presence of POR A287P (3).
Supplementary Methods
Steroid analysis in tissue explant culture supernatant by tandem mass spectrometry
Steroids were extracted from 500µL of cell media by liquid-liquid extraction using 5mL of dichloromethane. The dichloromethane was evaporated under nitrogen at 55˚C and the steroids reconstituted in 100µL of 50/50 methanol/water. LC-MS/MS was carried out employing a Xevo TQ mass spectrometer combined with an Acquity uPLC system with an electro-spray ionisation source in positive ion mode (Waters, Elstree). Steroids were eluted from a BEH C18 2.1 x 50mm 1.7µm column using a methanol/water gradient system. Solvent A was 0.1% formic acid in water, and B was 0.1% formic acid in methanol. The flow rate was 0.6 mL/min, and starting conditions were 45% B increasing linearly to 75% B over 5 minutes.
Quantitative PCR
Reactions were performed in 10 µl volumes on 96-well plates in reaction buffer containing 2x 
In vitro functional studies with humanized yeast microsomes
Saccharomyces cerevisiae strain W303B was transformed with V10-CYP17A1 and V10-CYP19A1, respectively, using a modification of the lithium acetate method as previously described (11) .
Wild-type human CYP19A1 full-length cDNA was amplified from pcDNA3.1/hsCYP19A1 (generous gift from Evan Simpson, Prince Henry's Institute of Medical Research, Melbourne, Australia) using the 5' sense primer CAAAGATCTGGAACACAAGATGGTTTTGGAAA and the 3' antisense primer CCAAGATCTGCCTTCTCTAGTGTTCCAGACAC that both included BglII restriction sites for subsequent cloning into yeast expression vector V10.
Yeast stably expressing wild-type human CYP17A1 or CYP19A1 were then transformed with yeast expression vector pYcDE2, containing the coding sequence of either wild-type or mutant (A287P or H628P) human P450 oxidoreductase (POR). Yeast microsomes co-expressing POR with CYP17A1 and CYP19A1, respectively, were prepared as previously described (11) . Microsomal enzyme activity assays were carried out with 0.5-5.0 µM PerkinElmer Life Sciences, Inc. (Boston, MA, USA); 17-Preg and 5α-17HP were custom synthesized as previously described (11, 12) . Table S1 . Table S1 . 
